Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
暂无分享,去创建一个
Johan Staaf | Mårten Fernö | Markus Ringnér | Johan Vallon-Christersson | Göran Jönsson | M. Ringnér | M. Fernö | P. Malmström | Å. Borg | N. Loman | B. Agnarsson | R. Barkardottir | J. Vallon-Christersson | G. Jönsson | J. Staaf | K. Holm | P. Bendahl | O. Johannsson | A. Arason | C. Hegardt | D. Grabau | Haukur Gunnarsson | L. Luts | Dorthe Grabau | Pär-Ola Bendahl | Niklas Loman | Cecilia Hegardt | Ake Borg | Karolina Holm | Rosa B Barkardottir | Bjarni A Agnarsson | Adalgeir Arason | Per-Olof Malmström | Haukur Gunnarsson | Lena Luts | Oskar Th Johannsson
[1] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[2] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[5] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[6] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[7] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[8] C. Hudis,et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.
[9] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[12] Carlos Caldas,et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.
[13] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[14] Marc Buyse,et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.
[15] Carsten Peterson,et al. Expression profiling to predict outcome in breast cancer: the influence of sample selection , 2002, Breast Cancer Research.
[16] E. Winer,et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.
[17] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[18] David Cameron,et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.
[19] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[20] R. Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .
[21] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[22] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[23] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[24] J. Foekens,et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. , 2004, Clinical breast cancer.
[25] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[26] Johan Staaf,et al. High‐resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization , 2007, Genes, chromosomes & cancer.
[27] S. Ménard,et al. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.
[28] Carlos Caldas,et al. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer , 2008, Breast Cancer Research.
[29] Mitch Dowsett,et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Nevins,et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. , 2007, The Lancet. Oncology.
[31] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[32] S. Paik. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. , 2007, The oncologist.
[33] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[34] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[35] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[36] M. Fernö,et al. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. , 1996, European journal of cancer.
[37] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[38] Johan Staaf,et al. Normalization of array-CGH data: influence of copy number imbalances , 2007, BMC Genomics.
[39] Gabriela Alexe,et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. , 2007, Cancer research.
[40] Josef Korinek,et al. Proceedings of the American Society of Clinical Oncology , 1982 .
[41] N. Brünner,et al. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] N. Brünner,et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.
[43] S. Ménard,et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[45] M. Delorenzi,et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[47] Joshy George,et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.
[48] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] S. Ménard,et al. Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.
[50] I. Ellis,et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.
[51] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[52] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.